irs program accomplishments · form 990 part iii · fy2024
What they reported doing
- #1 primary $0RAISING PUBLIC AWARENESS AND ADVOCATING FOR NEGLECTED DISEASE R&D:AS PART OF ITS MISSION, DNDI ADVOCATES FOR ENHANCED POLITICAL LEADERSHIP, INCREASED RESOURCES, AND AN ENABLING POLICY ENVIRONMENT TO STIMULATE R&D FOR NEGLECTED DISEASES. DNDI NORTH AMERICA ACTIVELY ADVOCATES FOR SOUND POLICIES, PARTICULARLY IN THE UNITED STATES, THAT WILL ENABLE GREATER NEEDS-DRIVEN R&D, INCLUDING APPROPRIATE INCENTIVES AND FINANCING MECHANISMS, INNOVATIVE REGULATORY PATHWAYS THAT EXPEDITE ACCESS, AND OPEN INNOVATION APPROACHES TO INTELLECTUAL PROPERTY MANAGEMENT THAT ENSURE THE WIDEST POSSIBLE SHARING OF RESEARCH KNOWLEDGE AND DATA.
named programs · 4 · from sources
What they call their work
4-in-1 Pediatric HIV Treatment
Created a heat-stable, strawberry-flavored granule formulation combining four antiretrovirals (LPV/r, ABC, 3TC) for young children living with HIV, approved in South Africa.
Acoziborole Development Program
Developed the first single-dose, all-oral treatment for sleeping sickness (human African trypanosomiasis), approved by the European Medicines Agency in 2026, enabling community-level administration and supporting disease elimination.
Open Innovation R&D Model
Collaborative, virtual drug development approach partnering with over 200 institutions globally to identify new chemical entities and repurpose existing drugs for neglected diseases.
Policy Advocacy for Neglected Disease R&D
Advocates for increased funding, improved regulatory pathways, and open intellectual property models to stimulate needs-driven research for neglected populations, particularly in the United States.
activities · 3 groups
What they do
-
Biomedical Research and Innovation 3 activities
- Building scientific capacity in low- and middle-income countriesBuilds scientific expertise in low-resource settings through clinical trials, research collaborations, and partnerships with over 200 global organizations, strengthening local research infrastructure and advancing equitable treatment development.
- Research and development of new treatments for neglected diseasesConducts over 40 research projects, including 21 focused on new chemical entities, and runs 16 clinical trials to discover, develop, and deliver new treatments for neglected diseases. This includes pioneering open-source drug discovery and developing innovative therapies such as acoziborole (a one-day, single-dose oral treatment for sleeping sickness) and a heat-stable, strawberry-flavoured pediatric HIV granule formulation.
- Securing regulatory approvals for neglected disease treatmentsObtains regulatory approvals for new treatments from major global health authorities, including the U.S. Food and Drug Administration, European Medicines Agency, and World Health Organization, enabling widespread distribution and use of newly developed therapies.
-
-
Healthcare Policy Advocacy 1 activity
- Advocacy for policy change in neglected disease R&DAdvocates for improved policies in the United States and globally to promote needs-driven research and development for neglected diseases, including reforms in financing, regulatory pathways, and open innovation in intellectual property management, while engaging with national health ministries, global bodies, and civil society.
-
-
Global Tuberculosis Drug Development and Access 1 activity
- Ensuring equitable access to treatments in underserved regionsConducts clinical trials in remote areas and supports delivery mechanisms to ensure life-saving treatments reach neglected populations, improving health outcomes in the world's poorest communities.
-
financials · form 990 · fy2024
revenue
Total revenue$6.22M
Contributions & grants$6.19M100%
Program service revenue$00%
Investment income$28K0%
Other revenue$0
expenses
Total expenses$6.35M
Program expenses81%
Admin / overhead10%
Fundraising9%
Salaries & benefits$1.75M
Grants paid out$3.67M
Largest expense lineCompensation
balance sheet
Total assets$2.50M
Cash$1.77M
Investments$0
Liabilities$1.53M
Net assets$977K
Liquid reserves3.4 mo
5 years on record · 2020–2024 · YoY revenue +43.0%
leadership · form 990 part vii · fy2024
Who runs it
paid leadership · 6
| Name | Title | Hours/wk | Compensation |
|---|---|---|---|
| DELALI ATTIPOE | EXECUTIVE DIRECTOR | 40 | $311K |
| RACHEL COHEN | SENIOR ADVISOR, GLOBAL POL | 40 | $282K |
| VISHAL GOYAL | SENIOR CLINICAL PROJECT AN | 40 | $177K |
| ILAN MOSS | HEAD OF MEDIA AND CONTENT | 40 | $170K |
| RON SYKES | SENIOR INDIVIDUAL GIVING MANAGER | 40 | $152K |
| SHIRLEY LEUNG | SENIOR HR BUSINESS PARTNER | 40 | $151K |
board members · 8
- AFRICA STEWART — BOARD MEMBER
- BENNETT SHAPIRO — BOARD MEMBER
- DARIN PORTNOY — CHAIR OF THE BOARD
- JOHN LAWRENCE — TREASURER
- KRISTINA TORGESON — BOARD MEMBER
- LUIS PIZARRO — BOARD MEMBER
- MEENA AHAMED — BOARD MEMBER
- SHING CHANG — SECRETARY
relationships · 19
Who they work with
- Doctors Without Borders / Médecins Sans Frontières Partner — Founding partner collaborating on research and development of treatments for neglected diseases.
- Doctors Without Borders / Médecins Sans Frontières (MSF) Partner — Founding partner in the creation of DNDi in 2003
- European Medicines Agency Government — Approved acoziborole, a treatment developed by DNDi.
- Indian Council of Medical Research Partner — Founding partner collaborating on research and development of treatments for neglected diseases.
- Indian Council of Medical Research Partner — Founding partner in the creation of DNDi in 2003
- Institut Pasteur Partner — Founding partner engaged in collaborative R&D for neglected disease treatments.
- Institut Pasteur Partner — Founding partner in the creation of DNDi in 2003
- International Research Community Partner — Collaborates with the international research community on drug R&D projects for neglected diseases.
- Kenya Medical Research Institute Partner — Founding partner in the creation of DNDi in 2003
- Kenya Medical Research Institute Partner — Founding partner involved in research and clinical development for neglected diseases.
- Malaysian Ministry of Health Partner — Founding partner collaborating on research and development of treatments for neglected diseases.
- Malaysian Ministry of Health Partner — Founding partner in the creation of DNDi in 2003
- Oswaldo Cruz Foundation Partner — Founding partner in Brazil collaborating on R&D for neglected diseases.
- Oswaldo Cruz Foundation Partner — Founding partner in the creation of DNDi in 2003
- Pharmaceutical Industry Partner — Collaborates with pharmaceutical industry partners to initiate and coordinate drug research and development.
- Public Sector Partner — Partners with public sector institutions to develop essential drugs for neglected diseases.
- World Health Organization Partner — Founding partner in the creation of DNDi in 2003
- World Health Organization Partner — Founding partner involved in research, development, and advocacy for treatments for neglected diseases.
- dndi.org Network — International website hosting detailed information on DNDi’s treatments and research portfolio.
strategies · 3
How they approach the work
Named approaches extracted from this org’s sources. Where others share an approach, follow it to see the full set of orgs running it.
- Collaborative R&D Coordination for Neglected Diseasesmethodology: collaborative_r&d_coordinationBy initiating and coordinating R&D collaborations across public, private, and research sectors, we address gaps in drug development for neglected diseases because cross-sector partnerships leverage diverse expertise and de-risk early-stage innovation.
- Needs-Driven Innovation Through Policy Advocacymethodology: needs-driven_r&d_policy_advocacyBy advocating for reforms in financing, regulation, and intellectual property, we accelerate access to treatments because systemic policy change redirects R&D priorities toward unmet medical needs rather than market profitability.
- Patient-Centered, Open-Source Drug Developmentmethodology: open_source_drug_discoveryBy centering R&D on patient needs and employing open-source discovery and repurposing, we develop affordable, accessible treatments because removing proprietary barriers accelerates innovation and ensures alignment with public health priorities.